Targeting CD22 for the Treatment of B-Cell Malignancies

Targeting CD22 for the Treatment of B-Cell Malignancies

Nikesh N Shah,1 Lubomir Sokol2 1Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA; 2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USACorrespondence: Lubomir SokolDepartment of Malignant Hema...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Shah NN, Sokol L
Format: Artykuł
Język:English
Wydane: Dove Medical Press 2021-07-01
Seria:ImmunoTargets and Therapy
Hasła przedmiotowe:
cd22
epratuzumab
inotuzumab ozogamicin
bispecific antibody
chimeric antigen receptor
lymphoma
acute lymphoblastic leukemia
Dostęp online:https://www.dovepress.com/targeting-cd22-for-the-treatment-of-b-cell-malignancies-peer-reviewed-fulltext-article-ITT

Internet

https://www.dovepress.com/targeting-cd22-for-the-treatment-of-b-cell-malignancies-peer-reviewed-fulltext-article-ITT

Podobne zapisy